Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed) | PAR 21 062

FAQs: Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed) (PAR-21-062)

1) What is this funding opportunity?

This is an NIH discretionary grant funding opportunity titled "Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed)" with FOA number PAR-21-062. It supports early-stage, innovative pilot projects focused on HIV/AIDS research questions that directly intersect with the mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

2) Which NIH institute is this tied to?

The opportunity is aligned with the NIDDK mission, meaning the strongest applications will clearly connect HIV-related mechanisms to NIDDK-relevant organs, tissues, and systems (for example metabolic disease, digestive and liver disease, kidney and urologic disorders, nutrition, obesity, endocrine and gastrointestinal processes).

3) What grant mechanism is used?

This uses the R21 mechanism, which is typically intended for exploratory, high-impact pilot studies that generate proof-of-concept or preliminary mechanistic insights rather than large, fully mature programs.

4) What is the budget ceiling mentioned in the opportunity?

The listed award ceiling is $200,000, signaling a small, focused budget that fits tightly scoped pilot work, method development, preliminary mechanistic studies, or narrowly targeted translational research.

5) Are clinical trials allowed under this FOA?

No. The opportunity is explicitly labeled "Clinical Trial Not Allowed." If human-subjects work is proposed, it must be designed so it does not meet the NIH definition of a clinical trial (for example, it should not assign participants to interventions to evaluate effects on health-related outcomes).

6) What types of research are encouraged (basic vs. translational vs. human subjects)?

The FOA is designed for basic and translational studies. Applicants may propose laboratory, preclinical, mechanistic, and human-subjects research aimed at understanding disease processes, as long as the work does not involve a clinical trial.

7) What is the main scientific focus of the FOA?

The core emphasis is on uncovering mechanisms of HIV pathogenesis that drive comorbidities, coinfections, and complications (CCCs) in NIDDK-relevant systems. In practical terms, the FOA is looking for studies that explain why and how HIV infection, long-term antiretroviral therapy, chronic inflammation, immune dysregulation, or viral persistence contribute to downstream health problems in metabolic, digestive, liver, kidney, urologic, nutrition, obesity, endocrine, and gastrointestinal contexts.

8) What does the FOA mean by comorbidities, coinfections, and complications (CCCs)?

Within the provided description, CCCs refer to downstream health problems linked to HIV pathogenesis that affect NIDDK-relevant organs and systems. The FOA is interested in mechanistic explanations for how HIV-related factors (including treatment-related and inflammation-related factors) contribute to these complications.

9) What kinds of NIDDK mission areas are specifically relevant?

The opportunity highlights NIDDK portfolio areas such as metabolic disease, diabetes-related pathways, digestive and liver diseases, kidney and urologic disorders, nutrition, obesity, and related endocrine and gastrointestinal processes.

10) Does the FOA support research on how HIV differs from similar conditions in people without HIV?

Yes. The description explicitly notes interest in the distinctive pathophysiology of HIV in NIDDK-relevant contexts, including studies that identify molecular pathways, cellular interactions, or host responses that make HIV-associated complications different from similar conditions in people without HIV.

11) Is HIV reservoir research within scope?

Yes. A major theme is HIV reservoirs, particularly biological mechanisms that allow HIV to persist in tissues that matter to NIDDK's mission. The FOA frames reservoir work as mechanistic research that can inform strategies for durable viral suppression or eventual eradication.

12) What types of HIV reservoir questions fit best for this FOA?

Based on the provided description, strong-fit reservoir projects could investigate: which cell types harbor persistent virus; what tissue microenvironments support persistence; how metabolic or inflammatory states influence reservoir dynamics; and which host pathways might be targeted to disrupt persistence in NIDDK-relevant compartments.

13) Is simply measuring HIV reservoirs enough for this opportunity?

The intent is not simply to measure reservoirs. The FOA emphasizes generating mechanistic insight that can serve as a foundation for more definitive studies and future interventions.

14) Are behavioral and social mechanisms allowed, or is it only biomedical?

Behavioral and social mechanisms are explicitly included. A major theme broadens scope beyond biology to include behavioral and social mechanisms, especially social determinants of health that impede outcomes and may worsen HIV-related comorbidities or influence viral reservoirs through multiple pathways.

15) What kinds of social determinants of health are mentioned as examples?

The description provides examples such as poverty, housing instability, food insecurity, access to care, and stigma, along with other contextual factors.

16) What type of behavioral or social science approach seems to be the best fit?

Based on the provided information, the strongest fit is likely projects that plausibly link social or structural exposures to mechanistic outcomes, pathways, or measurable disease processes in NIDDK-relevant systems, rather than projects that are purely descriptive.

17) Does the FOA require alignment with NIH HIV/AIDS research priorities?

Yes. The opportunity states an overarching expectation that projects align with NIH HIV/AIDS research priorities as outlined by the NIH Office of AIDS Research (OAR), specifically referencing NOT-20-018 regarding HIV/AIDS priorities and how HIV-related funding determinations are made.

18) Who is eligible to apply?

Eligibility is broad and includes domestic and non-domestic organizations. Eligible applicants include: state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses.

19) Are foreign organizations eligible?

Yes. The provided information explicitly includes foreign organizations among eligible applicants.

20) Are community-based and faith-based organizations eligible?

Yes. The FOA explicitly welcomes faith-based or community-based organizations as eligible applicants.

21) Are minority-serving institutions and tribally affiliated entities included?

Yes. The FOA highlights that other eligible applicants include institutions such as HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs. It also includes tribal governments that are not federally recognized.

22) Are U.S. territories or possessions eligible?

Yes. The provided description includes U.S. territories or possessions among eligible applicants.

23) Are federal agencies eligible to apply?

Yes. The description lists eligible federal agencies among eligible applicants.

24) What is the sponsoring agency and assistance listing identifier?

The sponsoring agency is the National Institutes of Health (NIH). The assistance listing is associated with CFDA number 93.847.

25) What is the activity/category focus for this opportunity?

The activity category is listed under health (and also tagged with food and nutrition), reflecting NIDDK's scope and the FOA's interest in HIV-related complications involving metabolic, digestive, liver, kidney, and nutrition-related systems.

26) What are the key dates mentioned?

The source information includes a creation date of January 11, 2021, and an original closing date listed as January 7, 2024.

27) What is the simplest way to describe the overall goal of the program?

Overall, it is a targeted call for exploratory HIV-related mechanistic research that directly informs NIDDK-relevant disease areas, with flexibility to incorporate biological, behavioral, and social pathways, provided the work stays within an R21 pilot scope and does not use a clinical trial design.